| Oct 30 |
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
|
| Oct 22 |
Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024
|
| Oct 20 |
We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate
|
| Sep 25 |
Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension
|
| Sep 17 |
Mineralys In Hypertension: Upcoming Catalysts And Strong Positioning
|
| Aug 28 |
Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference
|
| Aug 14 |
Mineralys Therapeutics, Inc. (MLYS) Q2 2024 Earnings Call Transcript
|
| Aug 13 |
Mineralys Therapeutics GAAP EPS of -$0.83 misses by $0.12
|
| Aug 13 |
Mineralys Therapeutics, Inc. 2024 Q2 - Results - Earnings Call Presentation
|
| Aug 13 |
Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
